MPT Product Development Database

Multipurpose Prevention Technologies (MPTs) are an innovative class of products that deliver varied combinations of HIV prevention, other STI prevention, and contraception and will improve the lives of women and families worldwide.

This database includes MPT products that are currently in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.

Click on the tables for MPT products in the development pipeline, listed by:
 
 
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
 
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
       
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
       
Key Word Search   
       

24 product(s) found



Dual Prevention Pill (DPP) Regimen

MPT in Development

Development Stage:
Clinical - Phase 4 (Post-marketing) Trial (C4)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Systemic - Pill/Tablet- Oral
Developer:
  • Population Council
  • Funding:
  • Children’s Investment Fund Foundation (CIFF)
  • National Institutes of Health (NIH)
  • U.S. Agency for International Development (USAID)
  • Funding Mechanism:
    NIH: NIMH R34
    USAID: EECO/USAID
    Active Ingredient:
  • Combined Oral Contraceptive (COC)
  • Emtricitabine (FTC)
  • Ethinyl Estradiol (EE)
  • Levonorgestrel
  • Tenofovir Disoproxil Fumarate (TDF)
  • Product Indications:
  • HIV
  • Pregnancy
  • Description:
    A 28-day contraceptive pill regimen that also provides protection against HIV. 21 pills will contain Truvada and EE/LNG; 7 pills will contain Truvada only. API compatibility (TDF/FTC with EE/LNG and excipients) confirmed. Acceptability studies with over-encapsulated Truvada and COC planned in Zimbabwe and South Africa to start in Q1 2021. Prototype development on hold while seeking additional funding.
    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    IMPT@cami-health.org

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    © Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.